Effects of hemodialysis on plasma oxylipins

Benjamin Gollasch1,2, Guanlin Wu1,3, Inci Dogan4

  • 1Experimental and Clinical Research Center (ECRC), a joint institution between the Charité University Medicine and Max Delbrück Center (MDC) for Molecular Medicine, Berlin-Buch, Germany.

Physiological Reports
|June 21, 2020
PubMed

Insights

Chronic kidney disease (CKD) patients undergoing hemodialysis show altered oxylipin profiles. Dialysis treatment increases specific cytochrome P450 (CYP) metabolites, suggesting these compounds may indicate disease and treatment effects.

Area of Science:

  • Biochemistry
  • Nephrology
  • Cardiovascular Medicine

Background:

  • Chronic kidney disease (CKD) is a significant risk factor for cardiovascular disease and mortality.
  • End-stage renal disease (ESRD) patients on hemodialysis have poor survival rates, largely due to cardiovascular complications.
  • The impact of impaired kidney function and hemodialysis on oxylipin metabolism remains unclear.

Purpose of the Study:

  • To investigate the effects of decreased renal function and hemodialysis on oxylipin profiles.
  • To determine if oxylipin levels can differentiate CKD patients from healthy individuals.
  • To assess the influence of renal replacement therapy on specific oxylipin pathways.

Main Methods:

  • Utilized high-performance liquid chromatography-mass spectrometry (HPLC-MS) lipidomics to measure oxylipins.
  • Analyzed oxylipins derived from cytochrome P450 (CYP) monooxygenase and lipoxygenase (LOX)/CYP ω/(ω-1)-hydroxylase pathways.
  • Compared oxylipin levels in 15 healthy individuals and 15 CKD patients before and after hemodialysis.

Main Results:

  • All four subclasses of CYP epoxy metabolites were found to be elevated post-hemodialysis.
  • Increased oxylipins in circulation were attributed to release and accumulation, not altered soluble epoxide hydrolase (sEH) activity.
  • The majority of LOX/CYP ω/(ω-1)-hydroxylase metabolites remained unchanged by hemodialysis.

Conclusions:

  • Oxylipin profiles effectively distinguish ESRD patients from healthy controls.
  • Hemodialysis treatment significantly influences the levels of specific oxylipin subclasses, particularly CYP metabolites.
  • These findings highlight the potential role of oxylipins as biomarkers in CKD and their modulation by renal replacement therapies.

Related Concept Videos

Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
407
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
905
Hemodialysis III: Nursing Management01:25

Hemodialysis III: Nursing Management

The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this...
543
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis01:30

Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

Patients with end-stage renal disease (ESRD) or those experiencing drug overdose often require extracorporeal methods to eliminate accumulated drugs and metabolites. Hemoperfusion, hemofiltration, and dialysis are the primary techniques to rapidly remove harmful substances without disrupting the patient's fluid and electrolyte balance. For those with compromised renal function, dosage adjustments of concurrent medications may be necessary during extracorporeal drug removal.Dialysis is a process...
239
Dialysis01:27

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
1.0K
Dialysis01:15

Dialysis

Dialysis is a diffusion-based purification process that separates analyte molecules from a complex matrix. This is accomplished by allowing molecules in the solution to pass through a semipermeable membrane into a liquid on the other side. The membrane is usually made of cellulose acetate or cellulose nitrate, and the second liquid must be miscible with the solution. Ions (e.g., chloride or sodium) or organic molecules (e.g., glucose) can pass through the membrane pores, which generally have...
1.4K